Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results

Full FY24 compared to full FY23: We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"), Clinical Genomics ("CG"), Biopharmaceutical Development ("BPD"), and Calibration Solutions ("CS"). Effective 4Q24 we changed our definition of non-GAAP adjusted operating income3 ("AOI") and non-GAAP adjusted operating income excluding unusual items to also exclude depreciation expense. Please see the reconciliation of those measures to GAAP operating (loss) income below. All prior per ...